Results 151 to 160 of about 51,672 (208)
Some of the next articles are maybe not open access.
Annals of Pharmacotherapy, 1992
OBJECTIVE: The primary objective of this article is to introduce readers to the use of a new agent, pamidronate. The article discusses its use in hypercalcemia of malignancy (HCM), osteolytic lesions, and Paget's disease. Pharmacokinetic data and clinical trials are reviewed, as well as adverse effects and dosage guidelines.
M J, Kellihan, P D, Mangino
openaire +4 more sources
OBJECTIVE: The primary objective of this article is to introduce readers to the use of a new agent, pamidronate. The article discusses its use in hypercalcemia of malignancy (HCM), osteolytic lesions, and Paget's disease. Pharmacokinetic data and clinical trials are reviewed, as well as adverse effects and dosage guidelines.
M J, Kellihan, P D, Mangino
openaire +4 more sources
Acta Crystallographica Section C Crystal Structure Communications, 2002
The title compound, disodium 3-ammonium-1-hydroxypropylidene-1,1-bisphosphonate pentahydrate, 2Na(+).C(3)H(9)NO(7)P(2)(2-).5H(2)O, is used for the diagnosis and treatment of a number of bone disorders. In the solid state, disodium pamidronate shows zwitterionic character and has four different modes of chelation to sodium.
Daniel, Vega +2 more
openaire +2 more sources
The title compound, disodium 3-ammonium-1-hydroxypropylidene-1,1-bisphosphonate pentahydrate, 2Na(+).C(3)H(9)NO(7)P(2)(2-).5H(2)O, is used for the diagnosis and treatment of a number of bone disorders. In the solid state, disodium pamidronate shows zwitterionic character and has four different modes of chelation to sodium.
Daniel, Vega +2 more
openaire +2 more sources
American Journal of Hospice and Palliative Medicine®, 1998
Pamidronate disodium appears beneficial in relieving metastatic bone pain refractory to NSAIDS and steroids. However, due to the invasiveness of administration and costs associated with the infusion, it should not be considered first line therapy. On the other hand, potential cost savings over conventional radiation therapy or surgery to relieve bone ...
K M, Strong, M L, McPherson
openaire +2 more sources
Pamidronate disodium appears beneficial in relieving metastatic bone pain refractory to NSAIDS and steroids. However, due to the invasiveness of administration and costs associated with the infusion, it should not be considered first line therapy. On the other hand, potential cost savings over conventional radiation therapy or surgery to relieve bone ...
K M, Strong, M L, McPherson
openaire +2 more sources